PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no pers Complete if Known Substitute for form 1449A/PTO Application Number 10/075,257 INFORMATION DISCLOSURE February 15, 2002 Filing Date STATEMENT BY APPLICANT First Named Inventor Yoram REITER Art Unit 1644 (use as many sheets as necessary) VANDERVEGT, FRANCOIS P **Examiner Name** Sheet of 3 Attorney Docket Number 02/23338 U.S. PATENT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where Cite No. 1 Publication Date DD-MMM-YYYY Examiner Document Number Relevant Passages or Relevant Applicant of Cited Document Initials* Figures Appear Number-Kind Code^{2 (if known)} 2003/0003535 02-Jan-2003 Reiter 1 2 2004/0086960 06-May-2004 Reiter 3 5,635,363 03-Jun-1997 Altman et al. 4 5,976,551 02-Nov-1999 Mottez et al. 5 6,011,146 04-Jan-2000 Mottez et al. 28-Nov-2000 6,153,408 Abastado et al. 6 FOREIGN PATENT DOCUMENTS Examiner Cite Pages, Columns, Lines, **Publication Date** Name of Patentee or Initials* Foreign Patent Documents T Where Relevant Passages DD-MMM-YYYY Applicant of Cited Document or Relevant Figures Appear Country Code3- Number4- Kind Code5 (if known) WO 01/72768 7 04-Oct-2001 Reiter

Date

Considered

Examiner

Signature

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

Under the Paperwork Reduction Act of 1995, no persons a

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

lection of information unless it contains a valid OMB control number. Complete if Known Application Number 10/075,257 Filing Date February 15, 2002 First Named Inventor Yoram REITER Group Art Unit 1644

(use as many sheets as necessary)			Group / it o.		1011			
(use as many sneets as necessary)				Examiner Na	me	VANDERV	EGT, FRANCOIS P	
Sheet		2	Of	3	Attorney Doc	ket Number	02/23338	
		OTHER PR	IOR ART -	NON PATI	ENT LITERA	ATURE DOC	UMENTS	
	ite lo. l	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²			
8		Abastado et al. "Dimerization of Soluble Major Histocompatibility Complex-Peptide Complexes Is Sufficient for Activation of T Cell Hybridoma and Induction of Unresponsiveness", Journal of Experimental Medicine, P.439-447, 1995. Abstract. P.439, Col.2, P.440, Col.1, § 1.						
9		Bousso et al. "Enrichment of Antigen-Specific T Lymphocytes by Panning on Immobilized MHC-Peptide Complexes", Immunology Letters, 59(2): 85-91, 1997. Abstract. P.86, Col.1.						
10		Denkberg et al. "Recombinant Human Single-Chain MHC-Peptide Complexes Made From E. Coli by In Vitro Refolding: Functional Single- Chain MHC-Peptide Complexes and Tetramers With Tumor Associated Antigens", European Journal of Immunology, 30(12): 3522-3532, 2000. Abstract. P.3524, Col.1, § 2, From Bottom.						
1	1	Garboczi et a Crystallizatio	il. "HLA-A2 on of Molect Antigenic Pe	P-Peptide Cor les Expresse eptides", Prod	mplexes: Reform ed in Escheric c. Natl. Acad.	olding and hia Coli and C Sci. USA, 89		
12	2	Kourilsky et al. "Immunological Issues in Vaccine Trials: T-Cell Responses", Preclinical and Clinical Development of New Vaccines, 95: 117-124, 1998. Lee et al. "Functional Cell Surface Expression by A Recombinant Single-Chain Class I Major Histocompatibility Complex Molecule With A Cis-Active Beta 2-Microglobulin Domain", European Journal of Immunology, 24(11): 2633-2639, 1994.						
13								
14	4	Ogg et al. "HLA-Peptide Tetrameric Complexes", Current Opinion in Immunology, 10: 393-396, 1998.						
13	5	Ojcius et al. "Dissociation of the Peptide-MHC Class I Complex Limits the Binding Rate of Exogenous Peptide", Journal of Immunology, 151(11): 6020-6026, 1993.						
16	6	Parker et al. "Peptide Binding to HLA-A2 and HLA-B27 Isolated From Eschericia Coli", The Journal of Biological Chemistry, 267(8): 5451-5459, 1992.						
17	7	Parker et al. "Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2", Journal of Immunology, 149(11): 3580-3587, 1992.						
Examiner Signature				_		Date Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no sons are required sespond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known			
Application Number	10/075,257		
Filing Date	February 15, 2002		
First Named Inventor	Yoram REITER		
Art Unit	1644		
Examiner Name	VANDERVEGT, FRANCOIS P		

Sheet		3	Of	3	Attorney Docket Number	02/23338	
		OTHER PRIOR	ART -	NON PATE	NT LITERATURE DOCU	MENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	18	Patamawenu et al. "Generation of Functional HLA-A2 Molecules Covalently Attached to Antigenic Peptides", Thesis (Master of Science in Biomedical Science), University of Maryland, 1988. Abstract.					
	19	Rammensee et al. "MHC Molecules as Peptide Receptors", Current Opinion Immunology, 5(1): 35-44, 1993.					
	20	Sylvester-Hvid et al. "A Single-Chain Fusion Molecule Consisting of Peptide, Major Histocompatibility Gene Complex Class I Heavy Chain and ?2- Microglobulin Can Fold Partially Correctly, But Binds Peptide Inefficiently", Scandinavian Journal of Immunology, 50(4): 355-352, 1999. P.358, Col.1, Fig.2, P.358, Col.2, ff, P.357, Col.1, § 1. Tafuro et al. "Reconstitution of Antigen Presentation in HLA Class I-Negative Cancer Cells With Peptide-?2M Fusion Molecules", European Journal of Immunology, 31(2): 440-449, 2001. Abstract. P.442, Fig.1.					
	21						
	22	Toshitani et al. "Expression of A Single-Chain HLA Class I Molecule in A Human Cell Line: Presentation of Exogenous Peptide and Processed Antigen to Cytotoxic T Lymphocytes", Proc. Natl. Acad. Sci. USA, 93(1): 236-240, 1996. Abstract, P.237, Col.2, Last §, Fig.1, P.236, Col.2, P.237, Col.2, § 2 From the Bottom, P.240, §1.					
	23						
	24	Zajac et al. "Gen Donors, After In-	eration of Vitro Sti	f Tumoricida mulation Wi	Il Cytotoxic T Lymphocytes th A Replicatin-Incompeten ope", International Journal of	t Vaccina Virus	

Examiner	Date	
Signature	Considered	

^a EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.